Make a donation

Friday, December 23 2016

Myeloma Matters: December 2016

  • pCODR Expert Review Committee Does Not Recommend Reimbursement for
  • Daratumumab (Darzalex)
  • My.eloma Canada is Pleased to Announce Revlimid® as First-Line Treatment for Non-Transplant Eligible Myeloma Patients Now Funded in Nova Scotia and the Yukon
  • Donate Securities Before the End of the Tax Year
  • Myeloma Canada Educational Webinars: Coming Soon in January 2017